Alterations in the level of neurotransmitters associated with the chronic treatment of antipsychotic drugs

Journal of the Pakistan Medical Association

Volumn 60, Issue 8, 2010, Pages 628-632

  Wasti, Afshan ^a   Siddiqui, Nikhat Ahmed ^b  

^a JINNAH UNIVERSITY FOR WOMEN   (Pakistan)

^b QASSIM UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; CLOZAPINE; DOPAMINE; HALOPERIDOL; HOMOVANILLIC ACID; SEROTONIN; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPAMINE RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; ENZYME ACTIVITY; HYPOTHALAMUS; LIVER LEVEL; LONG TERM CARE; MESENCEPHALON; NONHUMAN; RAT; SEROTONIN BRAIN LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; BRAIN; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; DOPAMINE; DOPAMINE ANTAGONISTS; HALOPERIDOL; NEUROTRANSMITTER AGENTS; RATS; SEROTONIN; SEROTONIN ANTAGONISTS; TRYPTOPHAN;

EID: 77956419830     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995; 3: 64-75.
2. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol 2007; 78: 133-64.
3. Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 2000; 47: 371-9.
4. Kapur S, Seeman P. Does fast dissociation from the dopamine d (2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360-9.
5. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20: 389-409.
6. Segman RH, Goltser T., Heresco-Levy U, Finkel B, Shalem R, Schlafman M, et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003; 3: 277-83.
7. Mortimer AM. Novel antipsychotics in schizophrenia. Expert Opin Investig Drugs 2004; 13: 315-29.
8. WU SN, Gao R, Xing QH, Li HF, Shen YF, Gu NF, et al. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacologica Sinica 2006; 27: 966-70.
9. Gunes A, Scordo MG, Jaanson P, Dahl ML. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl) 2007; 190: 479-84.
10. Sharma RP, Shapiro LE, Kamath SK, Soll EA, Watanabe MD, Davis JM. Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms. Neuropsychobiology 1997; 35: 5-10.
11. Heidbreder CA, Foxton R, Cilia J, Hughes ZA, Shah AJ, Atkins A, et al., Increased responsiveness of dopamine to atypical, but not typical antipsychotics in the medial prefrontal cortex of rats reared in isolation. Psychopharmacology (Berl) 2001; 156: 338-51.
12. Westerink BH, Kawahara Y, De Boer P, Geels C, De Vries JB, Wikstrom HV, et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001; 412: 127-38.
13. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002; 1: CD003198.
14. Markus CR, Olivier B, de Haan EH. Whey protein rich in alpha-lactalbumin increases the ratio of plasma tryptophan to the sum of the other large neutral amino acids and improves cognitive performance in stress-vulnerable subjects. Am J Clin Nutr 2002; 75: 1051-6.
15. Allegri G. Ragazzi E, Bertazzo A, Costa CV, Rocchi R. Tryptophan metabolism along the kynurenin pathway in rats. Adv Exp Med Biol 2003; 527: 481-96.
16. Moller SE. Tryptophan to competing aminoacid ratio in depressive disorder: relation to efficacy of antidepressive treatments. Acta Psychiatr Scand Suppl 1985; 325: 3-31.
17. Wasti A, Ghani R, Manji MA. Haloperidol induced variations in hematological indices. Pak J Med Sci 2004; 20: 197-200.
18. Reynolds G. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004; 18: 340-5.
19. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995; 14: 187-202.
20. Carpenter WT Jr. Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 1995; 15: 30S-5S.
21. Quintin P, Thomas P. Efficacy of atypical antipsychotics in depressive syndromes. Encephale 2004; 30: 583-9.
22. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153: 948-50.
23. Ruch W, Asper H, Burki HR. Effect of clozapine on the metabolism of serotonin in rat brain. Psychopharmacologia 1976; 46: 103-9.
24. Kozell L, Sandyk R, Wagner GC, Fisher H. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat. Life Sci 1987; 41: 1739-44.
25. Cihak A, Lamar C Jr, Pitot HC. L-tryptophan inhibition of tyrosine aminotransferase degradation in rat liver in vivo. Arch Biochem Biophys 1973; 156: 188-94.